Reliable MRD monitoring of ultra‐low BCR‐ABL1 levels is of increasing interest for patients with CML to identify individuals exhibiting deep molecular response who have optimal prospects for continuous treatment‐free remission. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.